[{"id":"c0d2e6aa-e2bf-4365-af70-bf037cd33910","acronym":"","url":"https://clinicaltrials.gov/study/NCT05751798","created_at":"2023-03-02T15:01:33.951Z","updated_at":"2024-07-02T16:34:25.778Z","phase":"Phase 1/2","brief_title":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05751798","lead_sponsor":"OSE Immunotherapeutics","biomarkers":" MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OSE-279"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/20/2022","start_date":" 12/20/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"}]